Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

作者：E B Haynes, Kushani Ediriwickrema, Sarah Lawless, Kevin Joyce, Matthew Wells, Jeffrey W. Smith, Kim Linton, Anna Santarsieri, George Follows, John Willan, Robert H. Osborn, Matthew R. Wilson, Pam McKay, M Naseem Baloch, Rory McCulloch, Mary Gleeson, David Wrench, David Foldes, Edward Kanfer, Kyaw Zin Maw, Andrea Kühnl, Matthew J. Ahearne, Mary Owen, Jane E. Norman, Ravi De Silva, Nimish Shah, Harriet Ambrose, Christopher P. Fox, J Naeemah Qasim, Graham P. Collins, Martha Vickers, David Tucker, Li Yuan Chan, Sunil Iyengar, Dima El‐Sharkawi, Rebecca Auer, Catherine Cox, Hwai Jing Hiew, Andrew Davies, Philippa Kelsey, David Lewis, Abigail E. Martin, Gavin Preston, Dominic Culligan, Angus Broom, William Wilson, Wendy Osborne, William Townsend · 发表于：Blood · 年份：2024 · DOI：10.1182/blood-2024-203781 · 被引用次数：7 · 研究领域：Health Systems, Economic Evaluations, Quality of Life、Biosimilars and Bioanalytical Methods、Pharmaceutical Economics and Policy

Background Glofitamab (Glofit) and Epcoritamab (Epco), CD3:CD20 bispecific monoclonal antibodies (BsABs), have demonstrated remarkable monotherapy activity in relapsed/refractory large B-cell lymphoma with complete response rates (CRR) of 39% in their registration trials and durable remissions in many responding patients. Data from these trials indicate similar outcomes independent of prior CAR-T exposure. These data led to the licencing of both drugs internationally in 2023; in the UK access was granted in 2023 initially via compassionate access prior to full license and reimbursement. Real world data is limited and urgently needed to better understand efficacy and tolerability. To our knowledge, this is the largest real world data set of both drugs. Aims To provide insights into efficacy, tolerability, and practical implications of delivery of BsABs in the real world setting. Methods A multicentre, retrospective analysis of anonymised data from patients treated on UK compassionate/early access schemes or licensed approval. Results 142 patients (pts.) were approved for Glofit at 26 UK centres: median age 68 years (range 25-90), 63% male and 99% performance status 0-2. Histological diagnoses included DLBCL (NOS) (61%), transformed follicular lymphoma (18%) and other NHL (20%). IPI score ≥3 in 54% (n=74), bulky disease in 23% (n=33) and a median of 3 lines of prior treatment with 15% (n=22) having received ≥4 lines. 60% (n=80) had prior CAR-T and 84% (n=117) were refractory to...